{"id":"https://openalex.org/W2586568461","doi":"https://doi.org/10.1182/blood.v128.22.3243.3243","title":"Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients","display_name":"Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2586568461","doi":"https://doi.org/10.1182/blood.v128.22.3243.3243","mag":"2586568461"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.3243.3243","doi":"https://doi.org/10.1182/blood.v128.22.3243.3243","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.3243.3243","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045479163","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook T. Kim","raw_affiliation_strings":["Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042332348","display_name":"Danielle M. Brander","orcid":"https://orcid.org/0000-0002-9581-2807","observed_orcids":["https://orcid.org/0000-0002-9581-2807"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle M. Brander","raw_affiliation_strings":["Duke University Medical Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010837659","display_name":"Jad Bsat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jad Bsat","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113981016","display_name":"Alexandra Savell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra Savell","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057423512","display_name":"Karen Francoeur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Francoeur","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015435609","display_name":"Jeffrey M. Hellman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Hellman","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caron A. Jacobson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035186913","display_name":"Ephraim P. Hochberg","orcid":"https://orcid.org/0000-0001-9050-7208","observed_orcids":["https://orcid.org/0000-0001-9050-7208"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ephraim Hochberg","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017708144","display_name":"Ronald W. Takvorian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Takvorian","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002103749","display_name":"Jeremy S. Abramson","orcid":"https://orcid.org/0000-0001-8467-9257","observed_orcids":["https://orcid.org/0000-0001-8467-9257"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy S. Abramson","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fisher","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":3.0575,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.91541192,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"128","issue":"22","first_page":"3243","last_page":"3243"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9900000095367432},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.8399999737739563},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8610000014305115},{"id":"https://openalex.org/keywords/fludarabine-cyclophosphamide-and-rituximab","display_name":"fludarabine-cyclophosphamide-rituximab","score":0.890999972820282},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.75},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.9639999866485596},{"id":"https://openalex.org/keywords/ighv-mutation-status","display_name":"IGHV mutation status","score":0.6639999747276306},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.8920000195503235},{"id":"https://openalex.org/keywords/unmutated-ighv","display_name":"unmutated IGHV","score":0.8769999742507935},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6759999990463257},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5870000123977661}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9797736406326294},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7432820796966553},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5948500633239746},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5894684791564941},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.463716983795166},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44702625274658203},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.4448601007461548},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4128516912460327},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.32549479603767395},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.32343626022338867},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.2924960255622864},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.28123730421066284},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2514379918575287}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.3243.3243","doi":"https://doi.org/10.1182/blood.v128.22.3243.3243","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.3243.3243","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2784934467","https://openalex.org/W3214577594","https://openalex.org/W2950378431","https://openalex.org/W4379980953","https://openalex.org/W4379981106","https://openalex.org/W2911357354","https://openalex.org/W2900467419","https://openalex.org/W7204700338","https://openalex.org/W2990290454","https://openalex.org/W4285387852"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"The":[2,149,293,421],"oral":[3],"BTK":[4],"inhibitor":[5],"ibrutinib":[6,121,135,198,207,477,623,729],"was":[7,298,316,323,331,340,573],"recently":[8],"approved":[9],"for":[10,40,142,199,514,735],"frontline":[11,106,140],"CLL":[12,42,74,89,123,145,164,660],"therapy":[13,39],"based":[14],"on":[15,206,606,728,781],"RESONATE-2,":[16],"which":[17,190],"included":[18,372,402,433],"only":[19,85,422],"patients":[20],"(pts)":[21],"age":[22,225,295],"\u226565":[23],"(Burger":[24],"et":[25,62,66,109],"al.,":[26,63,67,110],"2016).":[27,68],"In":[28,363,517,531],"the":[29,113,155,285,364,505,521,532,537,602,679],"absence":[30],"of":[31,47,88,120,134,157,281,367,400,457,465,468,486,494,523,582,590,601,614,664,689,701,709,718,785],"comparative":[32],"data,":[33],"FCR":[34,60,107,137,263,469,685],"remains":[35,626],"a":[36,352,552,587],"standard":[37,194],"initial":[38,229],"younger":[41,163],"pts,":[43,369,520,661],"particularly":[44],"in":[45,162,318,325,333,342,351,377,398,429,452,566,575,584,627,656],"light":[46],"recent":[48],"data":[49],"suggesting":[50],"that":[51],"mutated":[52],"IGHV":[53,315],"predicts":[54],"long":[55,567],"disease":[56,101],"free":[57],"survival":[58],"after":[59,256,261,503],"(Thompson":[61],"2016,":[64,284],"Fischer":[65],"However,":[69],"pts":[70,90,146,165,350,401,458,487,497,510,534,550,558,583,596,604,666,711,720],"with":[71,96,105,159,168,197,253,481,525,535,544,619,638,662,669,684,739],"higher":[72,677],"risk":[73,124],"such":[75],"as":[76,139,381,383],"del(17p)":[77,639],"and":[78,117,176,217,237,243,251,267,308,337,356,390,409,415,448,484,508,554,599,616,625,635,643,671,691,705,716,731],"unmutated":[79],"IGHVhave":[80],"less":[81],"durable":[82],"responses.":[83],"Moreover,":[84],"about":[86],"20%":[87,680],"will":[91,732],"achieve":[92],"complete":[93],"response":[94,173,254],"(CR)":[95],"bone":[97],"marrow":[98],"minimal":[99],"residual":[100,560,723],"negativity":[102],"(BM":[103],"MRD-neg)":[104],"(Boettcher":[108],"2012).":[111],"Given":[112],"favorable":[114],"toxicity":[115,250,371],"profile":[116],"substantial":[118],"efficacy":[119],"across":[122],"types,":[125],"we":[126],"developed":[127],"an":[128,782],"investigator-initiated,":[129],"multicenter":[130],"phase":[131],"II":[132],"study":[133,286],"plus":[136],"(iFCR)":[138],"treatment":[141,230],"young,":[143],"fit":[144],"(NCT02251548).":[147],"Methods":[148],"primary":[150,500],"objective":[151],"is":[152,183,191,272,528,539],"to":[153,188,201,248,645,698,737],"determine":[154],"rate":[156,522,681],"CR":[158,524,545,618,629,668,738],"BM":[160,515,526,572,620,674,714,740],"MRD-neg":[161,527,574,621,628],"treated":[166],"upfront":[167],"iFCR.":[169],"Secondary":[170],"endpoints":[171],"include":[172],"rate,":[174],"PFS,":[175],"safety/tolerability.":[177],"Ibrutinib":[178],"420":[179],"mg":[180],"daily":[181],"monotherapy":[182],"started":[184],"7":[185],"days":[186],"prior":[187],"FCR,":[189],"given":[192,471],"at":[193,290,296,489,630],"doses":[195],"together":[196],"up":[200],"6":[202,466,612],"cycles.":[203],"Responders":[204],"continue":[205,727],"maintenance":[208,624,730],"until":[209],"progression":[210],"or":[211,546,787],"unacceptable":[212],"toxicity.":[213],"Growth":[214],"factor":[215,703],"support":[216,704],"antimicrobial":[218,706],"prophylaxis":[219],"are":[220,246,597],"mandatory.":[221],"Eligibility":[222],"criteria":[223,245],"include:":[224],"\u2264":[226,563],"65,":[227],"requiring":[228],"by":[231,274,569],"IW-CLL":[232,244],"criteria,":[233],"ECOG":[234],"PS":[235],"\u22641,":[236],"adequate":[238],"organ":[239],"function.":[240],"CTCAE":[241],"v4":[242],"used":[247],"evaluate":[249],"efficacy,":[252],"evaluations":[255],"3":[257,385,439,443,446,450,461],"cycles,":[258],"2":[259,430],"mos.":[260,269],"final":[262],"(primary":[264],"endpoint":[265,501],"evaluation),":[266],"q6":[268],"thereafter.":[270],"MRD":[271],"assessed":[273],"4-color":[275],"flow":[276],"cytometry":[277],"(10-4sensitivity).":[278],"Results":[279],"As":[280],"August":[282],"1,":[283],"reached":[287],"full":[288],"accrual":[289],"35":[291,368,603],"pts.":[292,431],"median":[294,464,588],"enrollment":[297],"55":[299],"yrs":[300],"(range":[301,472,593],"38-65).":[302],"9/33":[303],"tested":[304,310,320,327,335,344,513,577],"(27%)":[305],"had":[306,312,476,488,551],"del(11q)":[307],"4/33":[309],"(12%)":[311],"del(17p).":[313],"Unmutated":[314],"present":[317,332,341],"20/31":[319],"(65%),":[321],"ZAP-70":[322],"positive":[324],"21/32":[326],"(66%),":[328],"TP53":[329],"mutation":[330,339],"2/31":[334],"(6%),":[336],"NOTCH1":[338],"2/21":[343],"(10%).":[345],"We":[346],"initially":[347],"enrolled":[348],"10":[349,631],"safety":[353],"lead-in":[354],"cohort":[355,366],"did":[357],"not":[358],"see":[359],"any":[360],"unexpected":[361],"toxicities.":[362],"entire":[365],"hematologic":[370,690],"grade":[373,394],"(gr)":[374],"4":[375,435],"neutropenia":[376,386],"1":[378,427,453,491],"pt":[379,454,475,609,637],"(3%),":[380],"well":[382],"gr":[384,413,419,426,434,438,442,445,449],"(15%),":[387],"thrombocytopenia":[388],"(18%),":[389],"anemia":[391],"(6%).":[392],"All":[393],"non-hematologic":[395],"toxicities":[396,693],"occurring":[397],">15%":[399],"nausea":[403],"(68%),":[404],"bruising":[405],"(35%),":[406],"fatigue":[407],"(29%),":[408],"rash":[410],"(21%)":[411,417],"(all":[412,418],"1/2)":[414],"diarrhea":[416],"1).":[420],"bleeding":[423],"events":[424],"were":[425,470,694],"epistaxis":[428],"SAEs":[432],"febrile":[436,482],"neutropenia,":[437],"atrial":[440],"fibrillation,":[441],"transaminitis,":[444],"pneumonia,":[447],"appendicitis":[451],"each.":[455],"9%":[456],"experienced":[459],"\u2265gr":[460],"infection.":[462],"A":[463],"cycles":[467,613],"3-6).":[473],"One":[474,608],"dose":[478,492],"reduction":[479,493],"(pt":[480],"neutropenia),":[483],"18%":[485],"least":[490],"chemotherapy.":[495],"Twenty-eight":[496],"have":[498,511,559,712,721],"undergone":[499],"re-staging":[502],"completing":[504],"iFCR":[506,615,652],"combination":[507],"26":[509,519],"been":[512],"MRD.":[516],"these":[518,719],"39%":[529,542,663],"(10/26).":[530],"28":[533],"re-staging,":[536],"ORR":[538],"100%,":[540],"including":[541,579],"(11/28)":[543],"CRi.":[547],"17/28":[548],"(61%)":[549],"PR,":[553],"all":[555,595,717],"17":[556],"PR":[557,642,710],"lymph":[561,724],"nodes":[562],"2.5":[564],"cm":[565],"axis":[568],"CT":[570],"imaging.":[571],"23/26":[576],"(89%),":[578],"13/17":[580],"(76%)":[581],"PR.":[585],"With":[586],"follow-up":[589],"12.1":[591],"months":[592,632],"0.1-21.1),":[594],"alive,":[598],"33":[600],"remain":[605],"treatment.":[607],"who":[610],"completed":[611],"achieved":[617,640,713],"declined":[622],"off":[633],"therapy,":[634],"one":[636],"MRD-pos":[641],"elected":[644],"pursue":[646],"allogeneic":[647],"stem":[648],"cell":[649],"transplant.":[650],"Conclusions":[651],"induces":[653],"deep":[654],"responses":[655],"previously":[657],"untreated":[658],"young":[659],"evaluable":[665],"achieving":[667,673],"BM-MRD-neg":[670],"89%":[672],"MRD-neg,":[675,715],"significantly":[676],"than":[678],"seen":[682],"historically":[683],"alone.":[686],"Low":[687],"rates":[688],"infectious":[692],"observed,":[695],"possibly":[696],"due":[697],"mandatory":[699],"use":[700],"growth":[702],"prophylaxis.":[707],"76%":[708],"small":[722],"nodes.":[725],"Pts":[726],"be":[733],"monitored":[734],"conversion":[736],"MRD-neg.":[741],"over":[742],"time.":[743],"Disclosures":[744],"Davids:":[745],"Genentech:":[746],"Consultancy,":[747,756,761,764],"Honoraria,":[748,752,765,770],"Research":[749,753,766,771,775,804],"Funding;":[750,754,767,776,805],"Infinity:":[751],"Janssen:":[755],"Honoraria;":[757,759,762],"Gilead:":[758,777,803],"Abbvie:":[760,792],"Pharmacyclics:":[763],"TG":[768],"Therapeutics:":[769,774],"Funding.":[772],"Brander:TG":[773],"Honoraria.":[778],"Jacobson:Kite:":[779],"Membership":[780],"entity's":[783],"Board":[784],"Directors":[786],"advisory":[788],"committees.":[789],"Abramson:Gilead:":[790],"Consultancy;":[791,793,796],"Seattle":[794],"Genetics:":[795],"Kite":[797],"Pharma:":[798],"Consultancy.":[799,801,815],"Fisher:Pharmacyclics:":[800],"Brown:Acetylon,":[802],"Celgene,":[806],"Roche/Genentech,":[807],"Gilead,":[808],"Infinity,":[809],"Janssen,":[810],"Pharmacyclics,":[811],"ProNai,":[812],"Sun":[813],"BioPharma:":[814]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":10}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-17T00:00:00"}